GRS

TRANSLATE

MENU menu

Close close menu

GRS Blog

PAST POSTS menu

Close close menu

US: New FDA Guidance on User Fee Waivers, Reductions, and Refunds

02/10/2011

FDA has issued a guidance titled User Fee Waivers, Reductions and Refunds for Drug and Biological Products that outlines FDA's policies for issuing waivers, refunds, or reductions in prescription drug user fees.

 

The newly issued guidance is a revision of a 1993 guidance titled Draft Interim Guidance Document for Waivers of and Reductions in User Fees.

 

Under the Prescription Drug User Fee Act (PDUFA), FDA is authorized to assess application fees for certain human drug and biological product applications or supplements. In addition, FDA can assess annual product fees for certain approved drug and biological products, and annual establishment fees for the facilities in which those products are made. 

 

Author: Greer Deal, Director of Global Regulatory Services (GRS)

Past Posts...

Stem Cells and Autism
18 September 2011